May. 16, 2025
SEONGNAM, SOUTH KOREA — Rznomics Inc., a South Korea-based clinical-stage biopharmaceutical company, has entered a strategic global research and licensing agreement with Eli Lilly and Company to co-develop RNA-editing therapies for sensorineural hearing loss. The collaboration marks another major step in Lilly’s expanding footprint in the field of genetic hearing restoration. Under the agreement, Rznomics will lead early-stage discovery using